SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 517-518

Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients

(3) Gimotty, Phyllis A a Guerry, DuPont a Flaherty, Keith a

a UNIVERSITY OF PENNSYLVANIA (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE;

BRAIN METASTASIS; BRAIN TUMOR; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; GLIOBLASTOMA; HUMAN; MELANOMA; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; METASTASIS; METHODOLOGY; MORTALITY; NOTE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SAMPLE SIZE; SKIN TUMOR; STANDARD;

BENCHMARKING; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; RESEARCH DESIGN; SAMPLE SIZE; SKIN NEOPLASMS;

EID: 39149103125 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2007.14.3156 Document Type: Editorial

Times cited : (5)

References (7)

1
- 34548646452
- Targeted therapy for metastatic melanoma
- Amaravadi RK, Flaherty KT: Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol 5:386-394, 2007
- (2007) Clin Adv Hematol Oncol , vol.5 , pp. 386-394
- Amaravadi, R.K.¹ Flaherty, K.T.²

2
- 1542351347
- Current developments of immunotherapy in the clinic
- Antonia S, Mule JJ, Weber JS: Current developments of immunotherapy in the clinic. Curr Opin Immunol 16:130-136, 2004
- (2004) Curr Opin Immunol , vol.16 , pp. 130-136
- Antonia, S.¹ Mule, J.J.² Weber, J.S.³

3
- 39149104690
- Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma: Determining progression-free and overall survival for future phase II trials
- Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma: Determining progression-free and overall survival for future phase II trials. J Clin Oncol 26:527-534, 2008
- (2008) J Clin Oncol , vol.26 , pp. 527-534
- Korn, E.L.¹ Liu, P.Y.² Lee, S.J.³

4
- 34047238978
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
- Ballman KV, Buckner JC, Brown PD, et al: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29-38, 2007
- (2007) Neuro Oncol , vol.9 , pp. 29-38
- Ballman, K.V.¹ Buckner, J.C.² Brown, P.D.³

5
- 0035881074
- Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
- Balch CM, Buzaid AC, Soong SJ et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
- (2001) J Clin Oncol , vol.19 , pp. 3635-3648
- Balch, C.M.¹ Buzaid, A.C.² Soong, S.J.³

6
- 35948935069
- Flexible two-stage design with sample size reassessment for survival trials
- Desseaux K, Porcher R: Flexible two-stage design with sample size reassessment for survival trials. Stat Med 26:5002-5013, 2007
- (2007) Stat Med , vol.26 , pp. 5002-5013
- Desseaux, K.¹ Porcher, R.²

7
- 35649022759
- Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line therapy
- Tang PA, Bentzen SM, Chen EX, et al: Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line therapy. J Clin Oncol 25:4562-4568, 2007
- (2007) J Clin Oncol , vol.25 , pp. 4562-4568
- Tang, P.A.¹ Bentzen, S.M.² Chen, E.X.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.